2025 HCPCS code Q5107
(Active) Effective Date: N/A Revision Date: N/A Pharmacy - Chemotherapy Medication Temporary Codes Q0035-Q9992 > Anti-Inflammatory Medication and Chemotherapy Medication Q5103-Q5111 Feed
Injection, bevacizumab-awwb, biosimilar, 10 mg
Modifiers may be applicable depending on the specific circumstances of the administration.
Medical necessity should be established through documentation indicating the patient's diagnosis, the stage and severity of their cancer, the rationale for using bevacizumab-awwb, and the expected clinical benefits.
Administered by healthcare professionals trained in intravenous infusions, typically oncologists or other specialists involved in cancer treatment. The appropriate dosage, combination with other chemotherapy agents if necessary and ongoing monitoring of patient response is the responsibility of medical professionals.
In simple words: This injection contains 10 mg of Mvasi™ (bevacizumab-awwb), a medicine similar to Avastin®, used to treat certain types of cancer. It's given through a vein and the dose depends on the type of cancer. It might be given along with other cancer medications.
Bevacizumab-awwb is a biosimilar to bevacizumab (Avastin®), administered intravenously to treat various cancers such as metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer. The dosage depends on the specific condition being treated and may be combined with other chemotherapeutic agents. It's available in single-dose vials of 100 mg/4 mL or 400 mg/16 mL (25 mg/mL).
Example 1: A patient with metastatic colorectal cancer receiving 10 mg of bevacizumab-awwb in combination with chemotherapy., A patient with glioblastoma receiving 10 mg of bevacizumab-awwb as part of their treatment plan., A patient with metastatic renal cell carcinoma receiving 10 mg of bevacizumab-awwb alongside other therapies.
Documentation should include the diagnosis, the specific type of cancer being treated, the dosage of bevacizumab-awwb administered, any other medications given concurrently, and the patient's response to treatment.
** Q codes are used for drugs, biologicals, and services not identified by national Level II codes when needed for Medicare claims.
- Specialties:Oncology, Hematology, potentially other specialties depending on the type of cancer being treated.
- Place of Service:Office, Inpatient Hospital, Outpatient Hospital, Independent Clinic, potentially others depending on the setting and payer guidelines.